A
Ann E. Bolton
Researcher at Novartis
Publications - 4
Citations - 4930
Ann E. Bolton is an academic researcher from Novartis. The author has contributed to research in topics: Imatinib mesylate & Imatinib. The author has an hindex of 4, co-authored 4 publications receiving 4753 citations.
Papers
More filters
Journal ArticleDOI
Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia
Stephen G. O'Brien,François Guilhot,Richard A. Larson,Insa Gathmann,Michele Baccarani,Francisco Cervantes,Jan J. Cornelissen,Thomas Fischer,Andreas Hochhaus,Timothy P. Hughes,Klaus Lechner,Johan Lanng Nielsen,Philippe Rousselot,Josy Reiffers,Giuseppe Saglio,John D. Shepherd,Bengt Simonsson,Alois Gratwohl,John M. Goldman,Hagop M. Kantarjian,Kerry Taylor,Gregor Verhoef,Ann E. Bolton,Renaud Capdeville,Brian J. Druker +24 more
TL;DR: Imatinib was superior to interferon alfa plus low-dose cytarabine as first-line therapy in newly diagnosed chronic-phase CML and was better tolerated than combination therapy.
Journal ArticleDOI
Frequency of Major Molecular Responses to Imatinib or Interferon Alfa plus Cytarabine in Newly Diagnosed Chronic Myeloid Leukemia
Timothy P. Hughes,Jaspal Kaeda,Susan Branford,Zbigniew Rudzki,Andreas Hochhaus,Martee L. Hensley,Insa Gathmann,Ann E. Bolton,Iris C. van Hoomissen,John M. Goldman,Jerald P. Radich +10 more
TL;DR: The proportion of patients with CML who had a reduction in BCR-ABL transcript levels of at least 3 log by 12 months of therapy was far greater with imatinib treatment than with treatment with interferon plus cytarabine.
Journal ArticleDOI
Effect of rifampicin on the pharmacokinetics of imatinib mesylate (Gleevec, STI571) in healthy subjects.
Ann E. Bolton,Bin Peng,Martine Hubert,Axel Krebs-Brown,Renaud Capdeville,Urs Keller,Michael Seiberling +6 more
TL;DR: Concomitant use of imatinib and rifampicin or other potent inducers of CYP4503A may result in subtherapeutic plasma concentrations ofImatinib, and alternative therapeutic agents with less potential for enzyme induction should be selected.
Journal ArticleDOI
Population pharmacokinetics of imatinib mesylate in patients with chronic-phase chronic myeloid leukaemia : results of a phase III study
Heinz Schmidli,Bin Peng,Gilles-Jacques Riviere,Renaud Capdeville,Martee L. Hensley,Insa Gathmann,Ann E. Bolton,A. Racine-Poon +7 more
TL;DR: In this paper, the authors investigated the biochemical and physiological covariates or comedications that affect the pharmacokinetics of imatinib mesylate in patients with chronic-phase chronic myeloid leukaemia (CP CML).